At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Topotecan +1 moredrug
Likely dose
Topotecan 4 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
In Brief
A Phase 2 clinical trial evaluating Topotecan and Bevacizumab for Ovarian Cancer and 2 related conditions. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsGlaxoSmithKline, Genentech, Inc.
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionJan 2010
Study CompletionAug 2011
TodayJul 2026
First PostedJun 22, 2006
Enrollment StartJun 1, 2006
Primary CompletionJan 1, 2010
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 20.0 years ago
Interventions
Topotecandrug
Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
Bevacizumabdrug
bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.